CAPS
A structured clinician interview. Studies should identify the version, rater training, and whether assessors knew the treatment timing.
A technical primer
How Outcomes Are Measured
PTSD outcome research is only as interpretable as the measures, timing, and comparisons used to record it. This page outlines what those choices can show—and what they cannot settle.
The focus is documentation: symptom instruments, functional measures, study design, and clear reporting in research involving ibogaine.
Start with the question
Scores are evidence, not a verdict
Research on PTSD and ibogaine may report lower symptom scores after treatment, but a number by itself does not establish why a change occurred, whether it lasted, or how it relates to daily life. Careful interpretation begins with the exact measure used, who completed it, and when it was completed.
For a wider introduction to the evidence questions around this topic, the site’s overview of ibogaine and PTSD research places outcome reports alongside safety concerns and uncertainty. The purpose here is narrower: to make the language of outcomes legible without treating any single score as proof of efficacy.
PTSD is a diagnostic construct with symptoms that can vary across people and over time; the National Institute of Mental Health overview of PTSD describes symptom domains that help explain why studies often use more than one questionnaire or interview.
Common instruments
What researchers ask, and how they ask it
The Clinician-Administered PTSD Scale, commonly called CAPS, is a structured clinical interview used to assess PTSD symptoms and diagnosis. The self-report PTSD Checklist, or PCL, asks participants to rate symptom severity themselves. Both can be useful, but they answer related—not identical—questions. Definitions and versions matter; the U.S. Department of Veterans Affairs description of CAPS-5 explains its role as a clinician-administered assessment.
PCL
A participant-completed PTSD symptom measure. It is efficient for repeated follow-up but remains a self-report instrument.
PHQ-9 & GAD-7
Brief measures of depressive and anxiety symptoms, often included because PTSD-related distress can overlap with both domains.
Function & disability
Scales of work, relationships, self-care, or daily activity can show whether symptom movement corresponds with practical functioning.
Meaningful timing
Baseline, follow-up, response, remission
Most reports compare a baseline score with one or more scores after treatment. The timing is consequential. A measure taken days after an intervention captures a different period than one taken at one month, six months, or longer. A complete report identifies every planned time point, how many participants supplied data at each one, and how missing follow-up was handled.
“Response” usually refers to reaching a predefined amount of improvement, often expressed as a percentage change from baseline. “Remission” usually refers to moving below a stated symptom threshold. Neither term has meaning without the study’s own definition, the instrument version, and the population to which it is applied. Reporting average change alongside individual distributions can keep a group mean from concealing very different participant experiences.
Published ibogaine reports may present before-and-after symptom questionnaires, sometimes alongside depression, anxiety, or well-being measures. Those reports can document what participants and investigators observed. They should also state whether the assessment was self-reported or clinician-rated, whether other care occurred, and whether the study was designed to test causation. For context on why design choices matter across research generally, randomized controlled trial methodology describes the role of allocation and comparison groups.
Outcome language is strongest when the measure, threshold, time point, and amount of missing data are all visible.
Study design
Why the same score can support different conclusions
An open-label study is one in which participants and investigators know what intervention is being received. It can be valuable for feasibility, safety observation, and early signal-finding, but it does not separate an intervention from expectation, selection, concurrent support, or change over time. A randomized controlled trial can improve causal interpretation by comparing groups, especially when assessment is blinded where feasible.
Open-label, single-group work
Useful for describing who participated, what was delivered, and how scores changed over the observed period. Results remain vulnerable to confounding and should not be read as a clean treatment effect.
Controlled, blinded work
A comparator group and blinded outcome assessment can reduce some bias. Design quality still depends on recruitment, retention, adherence, adverse-event reporting, and whether the comparison is credible.
Sample selection also shapes interpretation. A convenience sample, a self-referred group, or participants able to travel for care may not resemble the broader population of people with PTSD. Follow-up duration, attrition, and co-occurring substance use or mental health care should be described rather than treated as background detail. The site’s evidence review of ibogaine and PTSD examines these limits alongside the available study reports.
A clearer record
What future reports should make easy to find
Heterogeneous reporting makes studies difficult to compare. One paper may emphasize a mean questionnaire score, another a proportion meeting a response threshold, and another a short-term change without a fully reported follow-up denominator. Standardized reporting would not erase uncertainty, but it would make uncertainty easier to assess.
- Measure and assessor Name the instrument and version, state whether it was self-report or clinician-administered, and describe assessor blinding where applicable.
- Time points and retention Report baseline and every planned follow-up, including the number assessed at each point and reasons data are missing.
- Definitions before results Specify response and remission thresholds in advance, along with percentage-change calculations and the analysis population.
- Function and harms beside symptoms Present disability or functioning measures, concurrent care, and adverse events alongside symptom outcomes.
This level of detail is especially important where claims can outrun evidence. Ibogaine has recognized medical and legal complexity, and outcome reporting should never be separated from the safety context described in the discussion of ibogaine safety and risks. People seeking related substance-use context can also find a separate discussion at ibogaine for opioid addiction, where questions about outcomes and risk likewise require careful distinctions.
Questions of interpretation
Keep the denominator in view
-
What is the difference between response and remission?
Response generally means a predefined amount of improvement on a measure. Remission generally means a score has moved below a specified threshold. The exact definitions must be reported because they can differ across studies.
-
Why does follow-up length matter?
A score collected soon after an intervention describes a different time point from a score collected months later. Longer follow-up helps show whether observed changes were maintained, but it does not remove all sources of bias.
-
Can a symptom scale establish that ibogaine caused an outcome?
No. In an uncontrolled study, score changes may be associated with many factors, including expectation, concurrent care, selection, and natural change over time. Control groups and careful study design strengthen interpretation.
-
Why include function measures?
Symptoms and functioning overlap but are not interchangeable. Including both can clarify whether a measured symptom change was accompanied by a documented difference in day-to-day activity or participation.
Evidence requires room for uncertainty.
Understanding how outcomes are measured can make it easier to read study claims with care, especially when the underlying evidence is early, mixed, or incomplete.